Flosequinan

Flosequinan
Clinical data
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
Formula C11H10FNO2S
Molar mass 239.267 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Flosequinan is a quinolone vasodilator that was discovered and developed by Boots UK and was sold for about a year under the trade name Manoplax. It had been approved in 1992 in the US and UK to treat people with heart failure who could not tolerate ACE inhibitors or digitalis.[1]

Boots initiated a clinical trial called PROFILE to see if the drug could be useful in a wider population. The study was terminated early in 1993 due to increased mortality in the drug arm of the trial; preliminary results were published in a conference abstract by the PI Milton Packer and others, which promised data and analysis would be forthcoming in a future paper, but as of 2001 no such paper had been published.[2]

Boots withdrew it from the market in July 1993.[1][3]

References

  1. 1 2 Hosking, Patrick (25 July 1993). "Manoplax: from heart to heartbreak: With millions lost on its 'wonder". The Independent.
  2. ↑ van Veldhuisen, DJ; Poole-Wilson, PA (August 2001). "The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure". International Journal of Cardiology. 80 (1): 19–27. PMID 11532543.
  3. ↑ Associated Press (July 19, 1993). "Heart Failure Drug Manoplax Taken Off Market". AP News Archive.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.